Trospium Chloride Capsule, Extended Release
Product Images NDC 60429-098

7 FDA label images from Golden State Medical Supply, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 60429-098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60429 098 30ol Trospium Chloride Er 60 mg Caps Rev Aug 2014 Pmg Aug 2014 10 25 2018

60429 098 30ol Trospium Chloride Er 60 mg Caps Rev Aug 2014 Pmg Aug 2014 10 25 2018
Label for Trospium Chloride extended-release capsules, 60 mg strength, with a quantity of 30 capsules. The label shows the product is for once daily oral use and is distributed by Golden State Medical Supply, Inc. The NDC number is 60429-098-30 and the label mentions storage instructions at 20° to 25°C (68° to 77°F) with a reminder to see the package insert for dosage information. The label indicates the product is prescription only (Rx only).*
FDA Label Image

Structural Formula Of Trospium Chloride (Trospium Chloride Extended Release Capsules 1)

Structural Formula Of Trospium Chloride (Trospium Chloride Extended Release Capsules 1)
Chemical structure diagram of Trospium Chloride showing its molecular arrangement including a quaternary ammonium group and chloride ion.*
FDA Label Image

Figure 1: Mean (+sd) Concentration-time Profile For A Single 60 mg Oral Dose Of Trospium Chloride Extended-release Capsules In Healthy Volunteers (Trospium Chloride Extended Release Capsules 2)

Figure 1: Mean (+sd) Concentration-time Profile For A Single 60 mg Oral Dose Of Trospium Chloride Extended-release Capsules In Healthy Volunteers (Trospium Chloride Extended Release Capsules 2)
A line graph showing plasma concentration (mg/mL) over 24 hours post-dose for Trospium chloride extended-release capsules 60 mg. The graph illustrates a peak in plasma concentration around 4 hours post-dose followed by a gradual decline over time.*
FDA Label Image

Figure 2: Mean Change From Baseline In Urinary Frequency/24 Hours By Visit: Study 1 (Trospium Chloride Extended Release Capsules 3)

Figure 2: Mean Change From Baseline In Urinary Frequency/24 Hours By Visit: Study 1 (Trospium Chloride Extended Release Capsules 3)
A line graph showing the average change over weeks of treatment comparing placebo and Trospium chloride extended-release capsules (60 mg). The x-axis represents weeks of treatment (0, 1, 4, 12), and the y-axis shows average change with standard error. The graph includes p-values indicating statistical significance at various points.*
FDA Label Image

Figure 3: Mean Change From Baseline In Incontinence Episodes/week By Visit: Study 1 (Trospium Chloride Extended Release Capsules 4)

Figure 3: Mean Change From Baseline In Incontinence Episodes/week By Visit: Study 1 (Trospium Chloride Extended Release Capsules 4)
A line graph comparing average percentage change over a 12-week treatment period between placebo and Trospium Chloride extended-release capsules (60 mg). The y-axis shows average percentage change with standard error bars, and the x-axis shows weeks of treatment (0, 1, 4, 12). Trospium shows greater reduction at all time points with statistically significant p-values indicated.*
FDA Label Image

Figure 4: Mean Change From Baseline In Urinary Frequency/24 Hours By Visit: Study 2 (Trospium Chloride Extended Release Capsules 5)

Figure 4: Mean Change From Baseline In Urinary Frequency/24 Hours By Visit: Study 2 (Trospium Chloride Extended Release Capsules 5)
A line graph comparing the average change over time between placebo and Trospium Chloride extended-release capsules groups over 12 weeks of treatment. The x-axis shows weeks 0, 1, 4, and 12; the y-axis shows average change values with error bars for standard error. The Trospium Chloride group shows a greater decrease compared to placebo, with p-values indicating statistical significance at weeks 4 and 12.*
FDA Label Image

Figure 5: Mean Change From Baseline In Incontinence Episodes/week By Visit: Study 2 (Trospium Chloride Extended Release Capsules 6)

Figure 5: Mean Change From Baseline In Incontinence Episodes/week By Visit: Study 2 (Trospium Chloride Extended Release Capsules 6)
A line graph showing the average change over 12 weeks of treatment comparing placebo and trospium chloride extended-release capsules. The y-axis represents average change with standard error, and the x-axis shows weeks 0, 1, 4, and 12. Trospium chloride shows a greater negative change than placebo, with p-values indicating statistical significance at weeks 1, 4, and 12.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.